Tutorial video of the Diabetes Toolbox by the author

2021-12-04

Continuing Education


2021-11-28

Drug and Renal Function


2021-11-08

CLASSES

  • Jardiance® - New Health Canada Approval : Is indicated in adults with or without type 2 diabetes for the treatment of heart failure with reduced ejection fraction (Monograph).

2021-11-07

Insulins


2021-11-03

Drug and Renal Function


2021-11-02

Drug and Renal Function

  • Update of the Renal Function Adjustment Chart

CLASSES


2021-10-21

Insulin - Tresiba®


2021-10-14

Diabetes Canada


2021-10-03

Insulins

  • The summary table of insulins is now available here and is also available on the Insulins page (under the title)

2021-09-29

Lifestyle - Weight Management

Continuing Education - Invitation

  • The Management of Basal Insulins in the Context of Biosimilars, a Must!

Coverage - Infolettre RAMQ


2021-09-26

Insulin

Lifestyle

  • Add a New Tab - Weight Management (Content to Follow)

2021-09-22

Blood Glucose Monitoring

Diabetes Canada - Interactive Guide


2019-09-20

Drug and Renal Function

  • Update of the Renal Function Adjustment Chart

2021-09-01

Add a New Tab - Continuing Education

  • Events to Come (Content to Follow)
  • Presentation Archives (Content to Follow)

2021-08-17

CLASSES - Forxiga - New product monograph

  • New indication in Chronic Kidney Disease for FORXIGA.
    Indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease (CKD).
    AND
  • FORXIGA is not recommended in patients with an eGFR less than 25 mL/min/1.73m2. On dialysis FORXIGA is contraindicated in patients on dialysis

2021-07-19

RAMQ Reimbursement

  • As of July 7, 2021
    -With the exceptions provided for in this regulation, as of July 7, 2021, patients who are covered by the public drug insurance plan for a reference biologic drug will have until April 12, 2022 inclusive to switch to the biosimilar drug (See Attached Infolettre RAMQ)

2021-07-14

Coverage

  • RAMQ Codes update (PDF)

RAMQ Reimbursement


2021-06-22

Diabetes Québec


2021-06-16

Dexcom G6®


2021-06-12

Dexcom G6®

Coverage

  • RAMQ Codes update (PDF)

2021-05-26

Dexcom G6® - RAMQ coverage


2021-05-14

Insulin

Diabetes Canada - Resources


2021-04-18

Educational Videos - Hypoglycemia


2021-04-13

Resources


2021-04-11

Insulin - Classes


2021-03-28

Insulin

Digital Applications

Educational Videos


2021-03-21

Resources

Diabetes Québec


2021-03-20

Resources


2021-03-19

Blood Glucose Monitoring

  • Starting on March 22nd the Freestyle®Libre 2 will be available in pharmacies or on-line across the country

Classes


2021-03-16

Renal Function


2021-03-15

Blood Glucose Monitoring


2021-03-14

Lifestyle

Blood Glucose Monitoring


2021-03-13

Insulin

Classes


2021-03-11

Insulin

Lifestyle - Nutrition


2021-03-09

Classes


2021-03-08

Classes


2021-03-04

Classes

Blood Glucose Monitoring


2021-03-03

Classes

Insulin

Diabetes Québec


2021-02-25

Blood Glucose Monitoring

Classes


2021-02-18

Blood Glucose Monitoring

Insulin


2021-02-13

Blood Glucose Monitoring


2021-02-03

Coverage

  • The FreeStyle LibreTM Changes in eligibility and renewal criteria (see Coverage or Blood Glucose Monitoring tab)
  • RAMQ Codes update (PDF)

2020-01-24

Educational Videos - Blood Glucose Monitoring


2020-12-31

Educational Videos

  • Added a "Copy link" button. Allows you to copy the share link to the clipboard

Coverage

  • RAMQ Codes update (PDF)

2020-12-02

Blood Glucose Monitoring

  • Freestyle Libre 2 now approved by Health Canada

2020-11-16

Classes - Insulin

  • Modifications to cost per molecule files:
    - Classes (Steglatro discontinued + Invokamet very slight increase)
    - Insulin (Adding Admelog)

2020-11-15

Educational Videos


2020-11-14

Blood Glucose Monitoring

Insulin


2020-11-13

Coverage

  • RAMQ Codes update (PDF)

2020-01-11

Blood Glucose Monitoring

2020-10-28

Blood Glucose Monitoring


2020-10-18

Classes - Insulin


2020-09-29

Insulin

Classes


2020-09-22

Diabetes Canada


2020-09-17

Classes

  • Trulicity® - September 15 Health Canada gave a new indication for Trulicity: Indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of nonfatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease.

2020-08-25

Homepage

  • Tutorial video of the Diabetes Toolbox by the author

Classes + Insulin


2020-08-19

Insulin - Coverage

Coverage

  • RAMQ Codes update (PDF

2020-06-29

Lifestyle


2020-05-24

Resources

  • Injection Technic FIT Plus - Updating information

2020-04-29

Coverage

  • RAMQ Codes update (PDF)

2020-04-26

Blood Glucose Monitoring - FreeStyle LibreTM

  • Modification to the recognized indication for the payment of Freestyle LibreMC

2020-04-21

Diabetes Québec

Ressources


2020-04-18

Educational Videos


2020-04-10

CLASSES - SGLT2 Inhibitors

  • Forxiga® is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and CV risk factors or established CV disease (see CLINICAL TRIALS).

2020-04-07

Renal Function


2020-04-04

CLASSES - GLP-1R


2020-03-09

Digital Applications


2020-03-04

Classes + Insulin

  • New indications for Fiasp® and Victoza® see product monograph Fiasp® / Victoza®

2020-03-01

Classes


2020-02-09

Classes + Insulin

  • Adding of clinical trials

2020-01-15

Videos / Visual Tools / Applications


2019-12-26

Consultant

  • Jessie Haggai
    Proprietary Pharmacist - Diabetes Educator
    (see Contact us tab)

    Ms. Haggai joins the team as a consultant.

2019-12-25

Classes + Insulin


2019-11-30

Coverage

  • RAMQ Codes update (PDF)

2019-11-26

Classes + Insulin

  • The product monograph is now available

2019-11-16

Video


2019-11-14

GLP-1RA / Coverage


2019-11-10

Ressources


2019-11-03

Blood Glucose Monitoring


2019-10-27

Drug and Renal Function

  • Update of the Renal Function Adjustment Chart

Blood Glucose Monitoring

  • Freestyle LibreTM now working on Android


2019-10-10

Resources

Education

  • Nasal Glucagon BaqsimiTM - Health Canada Approval September 25 th
  • Nasal Glucagon BaqsimiTM - Information
  • Nasal Glucagon BaqsimiTM - Monograph

2019-10-03

Resources


2019-09-15

Blood Glucose Monitoring


2019-09-02

Education / Hypoglycemia / Glucagon


2019-08-15

Coverage

  • Glargine U300 Toujeo® now covered by the Quebec Health Insurance Board (RAMQ) according to certain criteria

2019-08-04

Blood Glucose Monitoring

  • Update of the Intercative Guide
  • Update of the Comparison Charts (PDF)

2019-07-19

Coverage

  • The FreeStyle LibreTM glucose monitoring flash system is now covered by the Quebec Health Insurance Board (RAMQ) according to certain criteria (see Coverage or Blood Glucose Monitoring tab)
  • RAMQ Codes update (PDF)

2019-06-20

GLP-1RA

  • Semaglutide Ozempic®
    New 4 mg flextouch maintenance pen. The 2 mg pen for the maintenance dose is no longer available

2019-05-31

Coverage

  • RAMQ Codes update (PDF)

2019-04-30

Drug and Renal Function

  • Update of the Renal Function Adjustment Chart

2019-04-11

Coverage

  • RAMQ Codes update (PDF)

2019-03-20

Blood Glucose Monitoring

  • New - Tab now completed

2019-03-07

Coverage

  • RAMQ Codes update (PDF)

2019-02-01

Coverage

  • RAMQ Codes update (PDF)

2018-12-19

Coverage

  • RAMQ Codes update (PDF)
  • SynjardyTM now code EN219

2018-11-23

Coverage

  • RAMQ Codes update (PDF)
  • Xigduo® and SynjardyTM now code EN150

2018-10-20

SGLT2

  • Adding - Ertugliflozin SteglatroTM
  • Adding - Ertugliflozin and Metformin SeglurometTM
  • Adding - Ertugliflozin and Sitagliptin SteglujanTM

Drug and Renal Function

  • New Chart Adjustment of the Medication with Renal Insufficiency

2018-10-01

Full update of the application

New

  • Addition of a search function
  • Overall improvement of performance and stability
  • Available soon for all Canadian provinces (in English only)

2018-09-27

Coverage

  • RAMQ Codes update (PDF) - Jardiance® now three codes EN148 - EN167 and EN179
  • Xigduo® and SynjardyTM now code EN199
  • Trajenta® now code EN148 and EN167
  • Degludec U100 and U200 now exception drugs (form)

2018-06-23

GLP-1RA

  • New document - Titration Protocol (Victoza® - Ozempic®- Trulicity® - AdlyxineTM)

2018-06-14

Drug and Renal Function

  • Update of the Renal Function Adjustment Chart

2018-05-26

Coverage

  • RAMQ Codes update (PDF) - Invokana® now three codes EN148, EN149 and EN167

2018-04-25

Lifestyle

  • New document - Meal and Physical Activity Log (PDF)

Insulin

  • New document - Basal Insulin Adjustments (PDF)

2018-04-15

Diabetes Canada

  • New Diabetes Canadian Guidelines as April 9, 2018

Drug and Renal function

  • New Chart Adjustment of the Medication with Renal Insufficiency

Classes

  • New Vascular Protection Data for SGLT2 and GLP-1RA classes

Blood Glucose Meters

Product Guide DQ (FR) ACCU-CHEK® Roche - Diabetes Care Ascencia Contour® - Diabetes Care Tutoriels OneTouch Verio ReflectTM

Blood Glucose Monitoring

Recommendation Tool / Frequency Interactive Guide SMBG

Strips

Reimbursement and Coding (FR) Clinical Situations Update 2017 (FR) (2017-11-15)

Codes / Indications RAMQ

EN23

When a sulfonylurea is not tolerated or ineffective.

  • Amaryl®

EN167

For the treatment of people with type 2 diabetes:
- As monotherapy when metformin and a sulfonylurea are contraindicated or not tolerated.

  • Invokana®
  • Januvia®
  • Jardiance®
  • Nesina®
  • Trajenta®

EN148

For the treatment of people with type 2 diabetes:
- In combination with metformin, when a sulfonylurea is contraindicated, not tolerated or ineffective.

  • Invokana®
  • Onglyza®
  • Januvia®
  • Jardiance®
  • Nesina®
  • Forxiga®

EN149

For the treatment of people with type 2 diabetes:
- In combination with a sulfonylurea, when metformin is contraindicated, not tolerated or ineffective.

  • Invokana®
  • Onglyza®
  • Nesina®
  • Forxiga®

EN150

For the treatment of people with type 2 diabetes:
When a sulfonylurea is contraindicated, not tolerated or ineffective; AND
- When the daily doses of metformin have been stable for at least a month.

  • Janumet®
  • Janumet®XR
  • Komboglyze®
  • JentaduetoTM
  • KazanoTM
  • Xigduo®

EN179

For the treatment of type 2 diabetes, in combination with one or more antidiabetic agents, in persons with a history of atherosclerotic heart disease (ASIC) or atherosclerotic vascular disease (ASK) and whose glycated hemoglobin (HbA1c) is ≥ 7%.

The nature of atherosclerotic heart disease (MCAS) or atherosclerotic vascular disease (MVAS) should be provided upon request by the Régie.

  • Jardiance®

EN219

For the treatment of people with type 2 diabetes whose optimal maximum dose of metformin has been stable for at least one month.
Individuals must also meet the requirements of the recognized indication for the payment of empagliflozin.

  • SynjardyTM

Exception Drug Codes (FR)

Cost

Cost price per molecule

NIHB Canada (Non-Insured Health Benefits)

Drug Benefit List

Patient Exception

Form

Form

Reimbursement
(exception drugs)

Ozempic®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes.
  • When a sulfonylurea is contraindicated, not tolerated or ineffective.
  • Authorization is given for a maximum weekly dose of 1mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

To note:

  • Unlike other GLP-1RA (Victoza and Trulicity), your patients do not need to have tried an iDPP4 or have a BMI > 30 to start treatment.
  • Both doses (0.5mg and 1mg) are reimbursed.


Victoza®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
  • When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
  • The maximum duration of each authorization is 12 months.
  • At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
  • Authorization is given for a maximum daily dose of 1.8 mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

Trulicity®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
  • When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
  • The maximum duration of each authorization is 12 months.
  • At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
  • Authorization is given for a maximum daily dose of 1.5 mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

Dulaglutide
Trulicity®
Liraglutide
Victoza®
Semaglutide
Ozempic®

Strips

Reimbursement and Coding (FR) Update 2017 (2017-11-15) (FR)

Dexcom G6®

Provincial Coverage and NIHB Eligibilty Criteria for RAMQ RAMQ Payment Authorization Request Form

Freestyle LibreTM

Autorisation of payment formulary RAMQ Eligibilty criteria et renewal

Diabetes Screening and Prevention

CANRISK Understanding and preventing type 2 diabetes(DQ)

Evaluation of the Risk of Cardio-Vascular Disease Tool

Patient Questionnaire

Education

A Practical Guide to Diabetes Management (DT2 de novo) The Basics Type 2 The Basics Type 1 Low Blood Sugar-hypoglycemia (DQ) High Blood Sugar-hyperglycemia (DQ) Hypoglycemia / Glucagon

Injection Technic FIT Plus

Insulin Pen Needle Length Site Selection and Rotation Lipohypertrophy (1) Lipohypertrophy (2) Pregnant Women (1) Pregnant Women (2) Older People (1) Older People (2) Kids Teens (1) Teens (2)

Sick-Day Management

Jessie Haggai Tool SADMANS (Appendix 8 DC) Urinary Tract Infections and Diabetes (DQ) Yeast Infections and Diabetes (DQ) Keeping People Safe During Sickdays Tool (DC)

Cannabis

Diabetes Canada Position Statement

Travel

Plan Your Trip Letter of Authorization

Driving

Drive Safe with Diabetes Licence (SAAQ) Law and Regulations Recommendations (DC) Assessment Form

Mental Health

Psychologists Quebec Association Quebec Association for Suicide Prevention See Digital Applications Tab

Diabetes Distress Scale (DDS)

Questionnaire How to use it in practice

Eye Care

Diabetes Canada Eye Health and Diabetes – Understanding Diabetic Retinopathy (DQ Retinopathy

Foot Care

AIISPQ (FR) Diabetes and Foot Care: A Checklist Rapid Screening for Neuropathy - Monofilament Testing Rapid Screening for Neuropathy - Vibration Tuning Fork Footcare and diabetes (DQ)

Pregnancy

Screening for Gestational Diabetes Mellitus (GDM) Gestational Diabetes (DQ) Pregnancy and Type 1 Diabetes (DQ) Pregnancy and Type 2 Diabetes (DQ)

Smoking and Diabetes

Management Recommendations J’ARRETE Smoking and Diabetes (DQ)

Ramadan

Diabetes Canada Position Statement Ramadan Calendar Dates

Diabetes Complications

Heart Health and Diabetes – Understanding Cardiovascular Diseases (DQ) Kidney Health and Diabetes – Understanding Diabetic Nephropathy (DQ) Nerve Health and Diabetes – Understanding Diabetic Neuropathy (DQ)

Miscellaneous

Diabetes Patient Care Flow Sheet for Adults (Appendix 3) Oral Health and Diabetes – Understanding Periodontal Disease (DQ Checklist for a Person with Type 2 Diabetes (DQ)

Vaccination

Diabetes Canada Protocole d'immunisation du Québec (PIQ)

- How can I add the app to the home screen of my mobile device?

To get the procedure to add this app, select the button corresponding to your mobile device. Note that the procedure may be slightly different depending on the version of the operating system used.

iPhone / iPad Android

- Do I have to download the application to be able to use it?

No. The application is hosted on a server and accessible via a web browser. The technologies used to develop this web application are the same as those used for the creation of websites. You can add a shortcut to the home screen of your mobile device.


- Does the application also work on my computer?

Yes. Although this application targets mobile devices first it will run properly on most modern web browsers (Mac and PC).


- The application does not seem to work normally.

Make sure Javascript is enabled in your device's web browser (usually enabled by default).


- How can I search for information in the app?

A search engine is located on the homepage below the navigation bar. You can clean the field by typing a new request or by using the to the right of the search button.